CG Oncology Appoints Proven Biopharmaceutical Commercial Leader Isabel Kalofonos as Chief Commercial Officer
Key Highlights
- ➤CG Oncology (CGON) appoints Isabel Kalofonos as Chief Commercial Officer
- ➤Kalofonos will lead commercial strategy ahead of potential cretostimogene launch
- ➤Cretostimogene clinical program includes more than 400 NMIBC patients
- ➤Cretostimogene has two Phase 3 trials: BOND-003 and PIVOT-006
- ➤Cretostimogene received FDA Fast Track and Breakthrough Therapy designations
Expert Statements
Arthur Kuan, Chairman and Chief Executive Officer of CG Oncology
“Isabel’s appointment reflects our commitment to ensuring we are well positioned to bring cretostimogene to as many patients as possible upon approval”
Arthur Kuan, Chairman and Chief Executive Officer of CG Oncology
“As we prepare for a potential first commercial launch, we are making deliberate investments in experienced leaders who have successfully built commercial organizations, developed differentiated strategies, and delivered product launches at scale.”
Arthur Kuan, Chairman and Chief Executive Officer of CG Oncology
“Isabel brings an outstanding track record of commercial execution across multiple therapeutic areas and stages of growth, and we are confident her expertise will be instrumental as we prepare to deliver on the full potential of cretostimogene.”
Isabel Kalofonos, Chief Commercial Officer of CG Oncology
“CG Oncology is entering an exciting and transformative period, and I am thrilled to join the company at such a pivotal time”
Isabel Kalofonos, Chief Commercial Officer of CG Oncology
“The clinical data generated to date for cretostimogene, the significant unmet need that remains for patients with bladder cancer, and the passion of the CG Oncology team make this a truly compelling opportunity.”
Isabel Kalofonos, Chief Commercial Officer of CG Oncology
“Having spent much of my career preparing companies for launch and building commercial organizations, I look forward to hitting the ground running, partnering across the organization, and helping ensure we are ready to successfully bring cretostimogene to patients.”
DALLAS, Oct. 13, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced the appointment of Isabel Kalofonos as Chief Commercial Officer. A highly accomplished biopharmaceutical executive with more than 20 years of commercial leadership experience, Ms. Kalofonos will lead the Company's commercial strategy and execution as CG Oncology advances toward the potential launch of cretostimogene grenadenorepvec and continues to establish itself as a leader in bladder cancer.
"Isabel’s appointment reflects our commitment to ensuring we are well positioned to bring cretostimogene to as many patients as possible upon approval," said Arthur Kuan, Chairman and Chief Executive Officer of CG Oncology. "As we prepare for a potential first commercial launch, we are making deliberate investments in experienced leaders who have successfully built commercial organizations, developed differentiated strategies, and delivered product launches at scale. Isabel brings an outstanding track record of commercial execution across multiple therapeutic areas and stages of growth, and we are confident her expertise will be instrumental as we prepare to deliver on the full potential of cretostimogene."
Get started
Create a free account to read the full story.